ArticleBritish journal of cancer2007
Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients.
Article in British journal of cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 101 citations in OpenAlex.
- TheInternational journal of molecular sciences · 2021Trial
- Concomitance of downregulated active caspase-3 and upregulated X-chromosome linked inhibitor of apoptosis protein as a sensitive diagnostic approach for breast cancer.Molecular and cellular biochemistry · 2019Trial
- Survivin knockout attenuates the progressiveness of BT549 triple negative-breast cancer cells: an in vitro study highlighting stemness and cellular stress response mechanisms.Molecular biology reports · 2025Article
- Dual sgRNA-directed knockoutNarra J · 2024Article
- BIRC5 expression by race, age and clinical factors in breast cancer patients.Breast cancer research : BCR · 2024Article
- Marine Natural Compound (Neviotin A) Displays Anticancer Efficacy by Triggering Transcriptomic Alterations and Cell Death in MCF-7 Cells.Molecules (Basel, Switzerland) · 2023Article
- Significance of combined TGF-β1 and survivin expression on the prognosis of patients with triple-negative breast cancer.Oncology letters · 2022Article
- Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts.Cancers · 2021Article
- AS1411-functionalized delivery nanosystems for targeted cancer therapy.Exploration of medicine · 2021Article
- Role of docosahexaenoic acid in enhancement of docetaxel action in patient-derived breast cancer xenografts.Breast cancer research and treatment · 2019Article
- Article
- Enhanced shRNA delivery by the combination of polyethylenimine, ultrasound, and nanobubbles in liver cancer.Technology and health care : official journal of the European Society for Engineering and Medicine · 2019Article
- Evaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situ.Einstein (Sao Paulo, Brazil) · 2018Article
- Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Ultrasound-targeted microbubble destruction (UTMD) assisted delivery of shRNA against PHD2 into H9C2 cells.PloS one · 2015Article
- Expression of CDKN1A/p21 and TGFBR2 in breast cancer and their prognostic significance.International journal of clinical and experimental pathology · 2015Article
- Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers.Molecular carcinogenesis · 2014Article
- CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin.Cancer biology & therapy · 2014Article
- Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.Breast cancer research : BCR · 2014Article
- Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma.Virchows Archiv : an international journal of pathology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Established clinico-pathological factors can place patients with breast cancer into good and poor prognostic categories, but even within these groups behaviour and response to treatment can differ. This study examined the value of cell cycle and apoptotic regulatory proteins in predicting behaviour in a poor prognostic group. A total of 165 patients, all of whom had died of breast cancer with duration of survival 12-127 months, median 38 months, were examined using immunohistochemistry for proliferation, apoptosis, p53, phosphorylated p53, p21, checkpoint kinase 2 (Chk2), bcl-2, bax, survivin and XIAP. All had received chemotherapy and/or hormonal therapy and were predominantly T2, node positive, grade III with only half oestrogen-receptor (ER) positive. High proliferation, phosphorylated p53, Chk2 and survivin expression correlated with grade III and lack of ER, whereas low proliferation, p21 and bcl-2 related to better grade and presence of ER. On univariate analysis grade, proliferation, phosphorylated p53, bcl-2, ER and survivin related to duration of survival. In multivariate analysis, grade (P=0.001) and survivin (P=0.005) were independent prognostic factors, grade III and presence of survivin relating to shorter survival. The latter was particularly for those patients receiving neoadjuvant therapy and adjuvant chemo- and hormonal therapy. The presence of the inhibitor of apoptosis protein survivin is a highly significant independent predictor of shorter duration of survival of patients with poor prognostic features, and merits investigation as a marker in other prognostic groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.